(Q39027797)

2 July 2019

review article

1 reference

title

MRD in AML: does it already guide therapy decision-making? (English)

1 reference

2 July 2019

1 reference

Gert Ossenkoppele

1

1 reference

2 July 2019

Gerrit Jan Schuurhuis

series ordinal

2

1 reference

2 July 2019

publication date

1 December 2016

1 reference

2 July 2019

Hematology / the Education Program of the American Society of Hematology

published in

1 reference

2 July 2019

volume

2016

1 reference

2 July 2019

issue

1

1 reference

2 July 2019

page(s)

356-365

1 reference

2 July 2019

Minimal residual disease monitoring after allogeneic transplantation may help to individualize post-transplant therapeutic strategies in acute myeloid malignancies

cites work

1 reference

12 December 2020

Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia

1 reference

12 December 2020

Acute Myeloid Leukemia

1 reference

12 December 2020

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia

1 reference

12 December 2020

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia

1 reference

12 December 2020

Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia

1 reference

12 December 2020

Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia

1 reference

12 December 2020

Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia

1 reference

12 December 2020

Functional characterization of minimal residual disease for P-glycoprotein and multidrug resistance protein activity in acute myeloid leukemia

1 reference

12 December 2020

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

1 reference

12 December 2020

AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML.

1 reference

12 December 2020

Assessment of Minimal Residual Disease in Standard-Risk AML.

1 reference

12 December 2020

Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations

1 reference

12 December 2020

Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.

1 reference

12 December 2020

MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia

1 reference

12 December 2020

Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease

1 reference

12 December 2020

Minimal residual disease in acute myeloid leukaemia

1 reference

12 December 2020

Human acute myeloid leukemia CD34+/CD38- progenitor cells have decreased sensitivity to chemotherapy and Fas-induced apoptosis, reduced immunogenicity, and impaired dendritic cell transformation capacities

1 reference

12 December 2020

Quantification of rare NPM1 mutation subtypes by digital PCR.

1 reference

12 December 2020

MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial

1 reference

12 December 2020

Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

1 reference

12 December 2020

Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

1 reference

12 December 2020

Minimal residual disease in acute myeloid leukemia--current status and future perspectives

1 reference

12 December 2020

High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival

1 reference

12 December 2020

Clinical significance of residual disease during treatment in childhood acute myeloid leukaemia

1 reference

12 December 2020

Residual disease detected by flow cytometry is an independent predictor of survival in childhood acute myeloid leukaemia; results of the NOPHO-AML 2004 study.

1 reference

12 December 2020

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group

1 reference

12 December 2020

Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

1 reference

12 December 2020

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

1 reference

12 December 2020

Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

1 reference

12 December 2020

The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy.

1 reference

12 December 2020

Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia.

1 reference

12 December 2020

Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.

1 reference

12 December 2020

Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients

1 reference

12 December 2020

Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.

1 reference

12 December 2020

The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia

1 reference

12 December 2020

Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.

1 reference

12 December 2020

Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation

1 reference

12 December 2020

Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms

1 reference

12 December 2020

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

1 reference

12 December 2020

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

1 reference

12 December 2020

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia

1 reference

12 December 2020

Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse

1 reference

12 December 2020

High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

1 reference

12 December 2020

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

1 reference

12 December 2020

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

1 reference

12 December 2020

Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

1 reference

12 December 2020

Tumor heterogeneity makes AML a "moving target" for detection of residual disease

1 reference

12 December 2020

Anthracycline dose intensification improves molecular response and outcome of patients treated for core binding factor acute myeloid leukemia

1 reference

12 December 2020

IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association

1 reference

12 December 2020

Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile

1 reference

12 December 2020

Detection of minimal disease in acute leukemia using flow cytometry: studies in a rat model for human acute leukemia

1 reference

12 December 2020

Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

1 reference

12 December 2020

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

1 reference

12 December 2020

Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia.

1 reference

12 December 2020

Early assessment of treatment response in patients with AML using [(18)F]FLT PET imaging

1 reference

12 December 2020

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol

1 reference

12 December 2020

Immunophenotypic evidence of leukemia after induction therapy predicts relapse: results from a prospective Children's Cancer Group study of 252 patients with acute myeloid leukemia

1 reference

12 December 2020

A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia

1 reference

12 December 2020

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

1 reference

12 December 2020

The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia

1 reference

12 December 2020

Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow

1 reference

12 December 2020

10.1182/ASHEDUCATION-2016.1.356

Identifiers

DOI

1 reference

2 July 2019

PMC publication ID

6142473

1 reference

2 July 2019

PubMed publication ID

27913502

1 reference

2 July 2019